logo

Clinical Trial Results

Share

Altamira Therapeutics Ltd. (CYTO) issued an update on the clinical trials with Bentrio in seasonal allergic rhinitis and acute COVID-19. The interim analysis of Australian NASAR trial in seasonal allergic rhinitis showed statistically significant improvement with Bentrio in nasal symptom primary endpoint...

Jazz Pharmaceuticals plc (JAZZ) and Zymeworks Inc. (ZYME) announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial examining zanidatamab in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma....

UroGen Pharma Ltd. (URGN) reported results from the first post-commercial utilization review of JELMYTO for pyelocalyceal solution. JELMYTO is approved for the treatment of adults with LG-UTUC, or low-grade upper tract urothelial cancer. "This study provides valuable insights into how physicians...

Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved...

Ocugen (OCGN) reported positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN. The study met both co-primary endpoints with robust immune responses. COVAXIN has been demonstrated in clinical trials to generate a broader immune...

Zai Lab Limited (ZLAB) and Novocure (NVCR) announced the LUNAR study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a randomized study evaluating the safety and efficacy of Tumor...

Takeda (TAK) announced that the totality of evidence from a pre-planned interim analysis of a Phase 3 study supports the efficacy and safety of TAK-755 as enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura or cTTP. Based on these data from the interim analysis, Takeda plans...

Biopharmaceutical company Pulmatrix, Inc. (PULM) announced Wednesday the successful completion of a Phase 1 trial evaluating safety and pharmacokinetics of PUR3100 in healthy volunteers for the treatment of acute migraine. PUR3100 uses the Company's iSPERSE formulation technology to create an orally...

Geron Corp. (GERN), a late-stage clinical biopharmaceutical company, announced Wednesday positive top-line results from its IMerge Phase 3 clinical trial evaluating imetelstat in lower risk myelodysplastic syndromes or MDS patients. Imetelstat is a novel, first-in-class telomerase inhibitor, being...

Gilead Sciences, Inc. (GILD) and EVOQ Therapeutics, Inc. (EVOQ) announced a collaboration and licensing agreement to advance EVOQ's technology for the treatment of rheumatoid arthritis and lupus. Gilead and EVOQ will collaborate on preclinical development. Gilead has the option to exclusively license...

Chemomab Therapeutics, Ltd. (CMMB) is up 35% in premarket trading Tuesday after reporting positive topline results from its NASH trial.

Follow RTT